Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 28 week, randomized, double-blind, placebo-controlled, two-part, multicenter, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skeletal muscle strength and function in older adults with sarcopenia (InvestiGAIT)

Trial Profile

A 28 week, randomized, double-blind, placebo-controlled, two-part, multicenter, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skeletal muscle strength and function in older adults with sarcopenia (InvestiGAIT)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimagrumab (Primary)
  • Indications Muscular atrophy
  • Focus Therapeutic Use
  • Acronyms InvestiGAIT
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Dec 2018 Status changed from recruiting to completed.
    • 17 Aug 2018 Planned End Date changed from 13 Jan 2019 to 16 Oct 2018.
    • 17 Aug 2018 Planned primary completion date changed from 16 Dec 2018 to 11 Oct 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top